Price Vision Group

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Price Vision Group sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 2 currently recruiting 5 completed early-phase tilt top decile by trial count

Price Vision Group: 10 sponsored US clinical trials, 2 recruiting.

Price Vision Group sponsors 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ectasia Corneal, with 1 trials.

Top-decile sponsor footprint

Price Vision Group ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

Corneal Crosslinking for Treatment of Corneal Neovascularization

NCT04787471
RECRUITING Phase 2

Comparison of Standard vs. Accelerated Corneal Crosslinking

NCT03922542
COMPLETED Phase 4

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

NCT05136443
TERMINATED

Effect of Xen Implantation on the Aqueous Humor Proteome

NCT04141865
COMPLETED Phase 2

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

NCT04051463
TERMINATED Phase 2

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

NCT03971357
COMPLETED NA

Effect of TrueTear Corneal Surface Imaging

NCT03637348
COMPLETED Phase 2

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

NCT01448213
COMPLETED Phase 2

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

NCT01143389
TERMINATED NA

Cross Linking for Treatment of Corneal Infection

NCT00912509

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 4 1

Therapeutic Areas

Ectasia Corneal 1
Corneal Neovascularization 1
Keratoconus 1

What is open in the Price Vision Group pipeline

2 recruiting of 10 indexed (20% open); 5 completed (50%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Ectasia Corneal (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Price Vision Group: open-pipeline peers nationwide

Peers matched on 10 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

Price Vision Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%10%20%30%40% Total trials Recruiting share Price Vision GroupAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAcera SurgicalAlign TechnologyAltruBioAlvernia University
Price Vision Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Price Vision Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Price Vision Group page

10 registered trials is a research-attention snapshot, not an endorsement of Price Vision Group or any single study.

  • 2 of Price Vision Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Ectasia Corneal is the condition Price Vision Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ectasia Corneal trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Price Vision Group pipeline card: 10 registered trials from official public datasets.Report a data error.